TGFB1 and melanoma: Fresolimumab (GC-1008; human TGF-β mAb), which blocks the activities of three isoforms of TGF-β, entered clinical trials for advanced renal cell carcinoma, malignant melanoma, high-grade glioma, and radiation-treated metastatic breast cancer, showing significant tumor responses.